MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock
$4,458K
(121.02%↑ Y/Y)
Proceeds from issuance of
common stock under...
$36K
(-10.00%↓ Y/Y)
Net cash provided by
financing activities
$4,494K
(-91.39%↓ Y/Y)
(decrease) increase in
cash, cash...
-$14,287K
(-121.56%↓ Y/Y)
Canceled cashflow
$4,494K
Change in fair value of
common stock warrant...
$3,940K
(7780.00%↑ Y/Y)
Stock-based compensation
expense
$1,598K
(-44.63%↓ Y/Y)
Accounts payable
$1,261K
(-17.15%↓ Y/Y)
Prepaid and other assets
-$624K
(79.74%↑ Y/Y)
Depreciation and
amortization
$331K
(-62.30%↓ Y/Y)
Net cash (used in)
provided by operating...
-$18,762K
(-229.38%↓ Y/Y)
Canceled cashflow
$7,754K
Net cash used in
investing activities
-$19K
(95.51%↑ Y/Y)
Deferred revenue
-$12,692K
(-133.29%↓ Y/Y)
Net loss
-$6,373K
(78.11%↑ Y/Y)
Collaboration and license
agreement receivable
$6,000K
Accrued expenses and
other liabilities
-$1,451K
(72.20%↑ Y/Y)
Purchases of property and
equipment
$19K
(-95.51%↓ Y/Y)
Back
Back
Cash Flow
Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc. (XLO)
source: myfinsight.com